Figure 4From: The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis Effects of ATO and nilotinib on cell surface antigen expression. A: The level of GPA induced by ATO and nilotinib alone or in combination (P < 0.01 vs. control). B/C: ATO and nilotinib alone or in combination elevated the expression of CD41 and CD11b (P < 0.05). Combined treatment was more potent in upregulating CD41 and CD11b levels as compared with single drug treatment. D: the expression of CD14 after drug treatment as compared with control (P > 0.05).Back to article page